Recursion Pharmaceuticals Grants RSUs Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Source: Newsfilter
Recursion Pharmaceuticals Inc. saw its stock price drop by 13.29% as it hit a 5-day low amid a broader market decline, with the Nasdaq-100 down 3.52% and the S&P 500 down 1.83%.
The company recently approved the grant of 2,991,840 restricted stock units (RSUs) to 33 new employees under its 2024 Inducement Equity Incentive Plan, aimed at attracting and retaining talent. This move is intended to enhance the company's competitive edge in the biotech sector, despite the current bearish sentiment reflected in the healthcare sector, where Recursion has a short interest of 35.15%.
This RSU grant highlights Recursion's commitment to long-term stability and talent retention, which could be crucial for its future growth, especially as it navigates significant regulatory hurdles and a challenging market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.110
Low
5.00
Averages
7.75
High
11.00
Current: 3.110
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MindWalk Holdings Bets on Biological Knowledge in Drug Discovery
- Importance of Biological Knowledge: MindWalk Holdings Corp. emphasizes that the true value in drug discovery lies in the connectivity of biological knowledge rather than just AI models, a perspective highlighted during the investor panel on June 15, which could influence industry investment directions.
- Technological Innovation: The launch of MindWalk's ReefIQ™ biological context layer technology connects 660 million biological patterns and 25 billion relationships, aiming to enhance AI model accuracy and reduce errors caused by fragmented data, thereby increasing the likelihood of successful drug discovery.
- Financial Performance: In its Q3 fiscal 2026 report, MindWalk reported revenue of CAD 4.2 million, a 52% year-over-year increase, and signed its first annual contract for the LensAI platform, marking a successful transition towards a sustainable revenue model.
- Market Competition: MindWalk faces intense competition in the AI drug discovery space from companies like Absci and Recursion, which tackle similar issues at different layers, and its biological context layer strategy may provide a unique market positioning.
See More
Investor Sentiment Analysis in Healthcare Sector Shows Divergence
- Divergent Investor Sentiment: As of May 31, 2026, short interest data reveals a stark divergence in investor sentiment within the healthcare sector, particularly among speculative biotech firms like Recursion Pharmaceuticals (RXRX) and Hims & Hers (HIMS), which have short interests of 35.15% and 28.41%, respectively, indicating strong bearish sentiment.
- Defensive Pharma Giants: In contrast, established pharmaceutical giants such as Eli Lilly (LLY) and Johnson & Johnson (JNJ) maintain minimal short positions of 0.95% and 0.96%, respectively, reflecting investor confidence in these mature companies amidst market volatility.
- Overall Sector Performance: Despite an 11.17% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has declined by 5.43%, highlighting the healthcare sector's underperformance in 2026, which may dampen long-term investor confidence.
- Top Shorted Stocks: The five most shorted mid- to mega-cap healthcare stocks as of May 31, 2026, include CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM), with short interests of 28.30% and 26.64%, respectively, reflecting heightened uncertainty surrounding these biotech firms in the current market environment.
See More
Investment Choices in Digital Drug Discovery Transformation
- Recursion's Growth Potential: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% year-over-year increase, despite a substantial net loss of approximately $644.8 million, highlighting the high costs and risks associated with drug discovery.
- Schrödinger's Steady Performance: Schrödinger generated about $255.9 million in revenue for FY 2025, marking a 23.3% increase, with a net loss of roughly $103.3 million, indicating stable growth in its software business and improved financial health.
- Risks and Challenges: Recursion faces significant regulatory hurdles and relies heavily on a small number of partners, meaning that the termination of agreements with companies like Roche could severely impact its revenue, while Schrödinger's dependence on unpredictable software sales cycles may affect revenue stability.
- Valuation Comparison: Recursion trades at a price-to-sales ratio of 26.1x, significantly higher than Schrödinger's 4.3x, reflecting a market premium on its future potential, but also indicating a higher investment risk.
See More
Comparing AI Pioneers in Drug Discovery
- Revenue Growth Comparison: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% increase, yet it faced a staggering net loss of approximately $644.8 million, highlighting the high costs associated with clinical trials and digital infrastructure, leaving its future profitability uncertain.
- Software Revenue Stability: Schrödinger generated around $255.9 million in revenue for FY 2025, marking a 23.3% increase, and while it reported a net loss of roughly $103.3 million, this represents an improvement from the previous year, indicating a gradual stabilization and expansion of its software business.
- Market Risk Analysis: Recursion's reliance on a small number of large partners like Roche and Bayer poses significant revenue risks, as the termination of any agreement could severely impact its income, compounded by competitive pressures from larger firms.
- Divergent Future Outlooks: Although Schrödinger is also currently operating at a loss, management anticipates a significant reduction in operating expenses in 2026, with annual contract value expected to grow by 10% to 15%, suggesting potential growth momentum for its business.
See More
Recursion Grants 2.99 Million RSUs to New Employees
- Employee Incentive Program: On May 26, 2026, Recursion approved the grant of 2,991,840 restricted stock units (RSUs) to 33 new employees under its 2024 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotech sector.
- Vesting Mechanism: Each RSU award will vest 1/4 of the shares on the first quarterly date following the one-year anniversary of the grant, and 1/16 of the shares on each subsequent quarterly date, ensuring employees remain committed to the company to receive full benefits, thus promoting long-term stability.
- Tech-Driven Biological Decoding: Recursion leverages its powerful Recursion OS platform, combining machine learning algorithms with vast biological and chemical datasets to advance the future of medicine, showcasing the company's innovative capabilities and market potential in the biotech field.
- Global Business Network: Headquartered in Salt Lake City, Recursion has established offices in Montreal, New York, London, and Oxford, creating a global business network that enhances its influence and expansion capabilities in international markets.
See More
Recursion Pharmaceuticals Faces Challenges Despite AI Innovations
- Poor Market Performance: Recursion Pharmaceuticals' stock has significantly underperformed broader equities over the past two years, recently hitting a new 52-week low, reflecting market skepticism regarding its AI-driven drug development strategy, which may lead to investor concerns about future performance.
- Partnerships Enhance Confidence: Collaborations with industry giants like Nvidia, Roche, Sanofi, and Bayer indicate potential in its technology; however, the lack of tangible results undermines market confidence in its financing capabilities and clinical progress.
- High R&D Costs: The time and costs associated with new drug development have risen sharply over the decades, and while Recursion aims to reduce these through its AI system, it currently lacks market-ready products and faces significant clinical and regulatory risks.
- Uncertain Clinical Trial Outlook: Although REC-4881 shows promise in treating Familial Adenomatous Polyposis, it remains in early-stage studies with no late-stage candidates, necessitating caution from investors regarding its future clinical advancements.
See More
MindWalk Holdings Bets on Biological Knowledge in Drug Discovery
- Importance of Biological Knowledge: MindWalk Holdings Corp. emphasizes that the true value in drug discovery lies in the connectivity of biological knowledge rather than just AI models, a perspective highlighted during the investor panel on June 15, which could influence industry investment directions.
- Technological Innovation: The launch of MindWalk's ReefIQ™ biological context layer technology connects 660 million biological patterns and 25 billion relationships, aiming to enhance AI model accuracy and reduce errors caused by fragmented data, thereby increasing the likelihood of successful drug discovery.
- Financial Performance: In its Q3 fiscal 2026 report, MindWalk reported revenue of CAD 4.2 million, a 52% year-over-year increase, and signed its first annual contract for the LensAI platform, marking a successful transition towards a sustainable revenue model.
- Market Competition: MindWalk faces intense competition in the AI drug discovery space from companies like Absci and Recursion, which tackle similar issues at different layers, and its biological context layer strategy may provide a unique market positioning.
See More
Investor Sentiment Analysis in Healthcare Sector Shows Divergence
- Divergent Investor Sentiment: As of May 31, 2026, short interest data reveals a stark divergence in investor sentiment within the healthcare sector, particularly among speculative biotech firms like Recursion Pharmaceuticals (RXRX) and Hims & Hers (HIMS), which have short interests of 35.15% and 28.41%, respectively, indicating strong bearish sentiment.
- Defensive Pharma Giants: In contrast, established pharmaceutical giants such as Eli Lilly (LLY) and Johnson & Johnson (JNJ) maintain minimal short positions of 0.95% and 0.96%, respectively, reflecting investor confidence in these mature companies amidst market volatility.
- Overall Sector Performance: Despite an 11.17% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has declined by 5.43%, highlighting the healthcare sector's underperformance in 2026, which may dampen long-term investor confidence.
- Top Shorted Stocks: The five most shorted mid- to mega-cap healthcare stocks as of May 31, 2026, include CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM), with short interests of 28.30% and 26.64%, respectively, reflecting heightened uncertainty surrounding these biotech firms in the current market environment.
See More
Investment Choices in Digital Drug Discovery Transformation
- Recursion's Growth Potential: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% year-over-year increase, despite a substantial net loss of approximately $644.8 million, highlighting the high costs and risks associated with drug discovery.
- Schrödinger's Steady Performance: Schrödinger generated about $255.9 million in revenue for FY 2025, marking a 23.3% increase, with a net loss of roughly $103.3 million, indicating stable growth in its software business and improved financial health.
- Risks and Challenges: Recursion faces significant regulatory hurdles and relies heavily on a small number of partners, meaning that the termination of agreements with companies like Roche could severely impact its revenue, while Schrödinger's dependence on unpredictable software sales cycles may affect revenue stability.
- Valuation Comparison: Recursion trades at a price-to-sales ratio of 26.1x, significantly higher than Schrödinger's 4.3x, reflecting a market premium on its future potential, but also indicating a higher investment risk.
See More
Comparing AI Pioneers in Drug Discovery
- Revenue Growth Comparison: Recursion Pharmaceuticals reported nearly $74.7 million in revenue for FY 2025, reflecting a 26.9% increase, yet it faced a staggering net loss of approximately $644.8 million, highlighting the high costs associated with clinical trials and digital infrastructure, leaving its future profitability uncertain.
- Software Revenue Stability: Schrödinger generated around $255.9 million in revenue for FY 2025, marking a 23.3% increase, and while it reported a net loss of roughly $103.3 million, this represents an improvement from the previous year, indicating a gradual stabilization and expansion of its software business.
- Market Risk Analysis: Recursion's reliance on a small number of large partners like Roche and Bayer poses significant revenue risks, as the termination of any agreement could severely impact its income, compounded by competitive pressures from larger firms.
- Divergent Future Outlooks: Although Schrödinger is also currently operating at a loss, management anticipates a significant reduction in operating expenses in 2026, with annual contract value expected to grow by 10% to 15%, suggesting potential growth momentum for its business.
See More
Recursion Grants 2.99 Million RSUs to New Employees
- Employee Incentive Program: On May 26, 2026, Recursion approved the grant of 2,991,840 restricted stock units (RSUs) to 33 new employees under its 2024 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotech sector.
- Vesting Mechanism: Each RSU award will vest 1/4 of the shares on the first quarterly date following the one-year anniversary of the grant, and 1/16 of the shares on each subsequent quarterly date, ensuring employees remain committed to the company to receive full benefits, thus promoting long-term stability.
- Tech-Driven Biological Decoding: Recursion leverages its powerful Recursion OS platform, combining machine learning algorithms with vast biological and chemical datasets to advance the future of medicine, showcasing the company's innovative capabilities and market potential in the biotech field.
- Global Business Network: Headquartered in Salt Lake City, Recursion has established offices in Montreal, New York, London, and Oxford, creating a global business network that enhances its influence and expansion capabilities in international markets.
See More
Recursion Pharmaceuticals Faces Challenges Despite AI Innovations
- Poor Market Performance: Recursion Pharmaceuticals' stock has significantly underperformed broader equities over the past two years, recently hitting a new 52-week low, reflecting market skepticism regarding its AI-driven drug development strategy, which may lead to investor concerns about future performance.
- Partnerships Enhance Confidence: Collaborations with industry giants like Nvidia, Roche, Sanofi, and Bayer indicate potential in its technology; however, the lack of tangible results undermines market confidence in its financing capabilities and clinical progress.
- High R&D Costs: The time and costs associated with new drug development have risen sharply over the decades, and while Recursion aims to reduce these through its AI system, it currently lacks market-ready products and faces significant clinical and regulatory risks.
- Uncertain Clinical Trial Outlook: Although REC-4881 shows promise in treating Familial Adenomatous Polyposis, it remains in early-stage studies with no late-stage candidates, necessitating caution from investors regarding its future clinical advancements.
See More
